pemetrexed
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pancreatic Cancer
Conditions
Pancreatic Cancer
Trial Timeline
Oct 1, 2003 → Apr 1, 2005
NCT ID
NCT00490373About pemetrexed
pemetrexed is a phase 2 stage product being developed by Eli Lilly for Pancreatic Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00490373. Target conditions include Pancreatic Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00035061 | Phase 2 | Completed |
| NCT03955042 | Phase 1 | Completed |
| NCT01473563 | Phase 2 | Completed |
| NCT00916630 | Phase 1 | Completed |
| NCT00732303 | Phase 2 | Terminated |
| NCT00864513 | Phase 2 | Terminated |
| NCT00520936 | Phase 2 | Completed |
| NCT00523419 | Phase 2 | Completed |
| NCT00540241 | Pre-clinical | Completed |
| NCT00497770 | Pre-clinical | Completed |
| NCT00316225 | Phase 2 | Completed |
| NCT00380718 | Approved | Completed |
| NCT00377520 | Phase 2 | Completed |
| NCT00190918 | Phase 2 | Completed |
| NCT00330915 | Phase 2 | Completed |
| NCT00109096 | Phase 2 | Completed |
| NCT00106002 | Phase 2 | Completed |
| NCT00216099 | Phase 2 | Completed |
| NCT00190983 | Phase 2 | Completed |
| NCT00216216 | Phase 2 | Terminated |
Competing Products
20 competing products in Pancreatic Cancer